


## Actionable Results – Fast Turnaround – No Tissue Requirement

### Personalized Treatment Decisions Across All Risk Groups



## Where does the ArteraAI Prostate Test fit in the patient journey?



The test is designed to support clinical decision-making through **risk stratification**, suitability for **active surveillance**,<sup>a</sup> suitability of **abiraterone** adjunctive therapy<sup>c</sup>, and prediction of **ST-ADT benefit**<sup>b</sup> for patient with localized prostate cancer.

## How can the prognostic and predictive results be used to guide treatment decisions?

		Results Provided Across NCCN Risk Groups					
		Very Low	Low	Favorable Intermediate	Unfavorable Intermediate	High	Very High
MMAI Prognostic Biomarker		10-Year Risk of Distant Metastasis					
		10-Year Risk of Prostate Cancer Specific Mortality					
		Active Surveillance Insights (Adverse Pathology at RP)					
						Abiraterone Insights (Metastasis Free Survival)	
ST-ADT Biomarker				Prediction of ST-ADT Benefit			

<sup>a</sup>For patients with NCCN very low-, low-, or favorable-intermediate risk.

<sup>b</sup>For patients with NCCN intermediate-risk.

<sup>c</sup>For patients with NCCN very high-, high-risk.

# Multimodal artificial intelligence (ArteraAI Prostate Test) is the only predictive ST-ADT tool recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer<sup>1</sup>



## LOW OUT OF POCKET (OOP) COSTS

No OOP for Medicare patients and Financial Assistance Program available for those with more than \$285 OOP.



## DOES NOT CONSUME TISSUE

Analysis uses image data from existing biopsy slides with no additional staining or preparation required



## RAPID TURNAROUND

Results can be shared within 1-2 days after receipt of the patient's specimen by our CLIA lab



## DEVELOPED FROM LARGE DATASETS

Validated using data from over 9000 patients enrolled in multiple Phase 3 randomized trial across treatment modalities with up to 20 years of follow-up



## REPRESENTS DIVERSE POPULATIONS

Consistent prognostic performance between African American and non-African American men<sup>5</sup>

"I think that this test is really transformative.

We have never had any predictive biomarkers to use in clinical practice until now.  
We have been talking about this and wanting a tool like this for decades."

- Daniel E. Spratt, MD, University Hospitals Seidman Cancer Center, Case Western Reserve University



Sample Test Report



Test Guide

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

AI, artificial intelligence; CLIA, Clinical Laboratory Improvement Amendments; NCCN, National Comprehensive Cancer Network; ST-ADT, short-term androgen deprivation therapy.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 4, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. Esteva A, et al. *NPJ Digit Med*. 2022;5(1):71. 3. Data on File. Artera, 2023. 4. Spratt DE, et al. *NEJM Evidence*. 2023;2(8). 5. Roach M, et al. *JCO Clin Cancer Inform* 9, e2400284(2025)



artera.ai  
Customer Service can be reached at 1-650-239-7018  
Artera is located at 108 First Street, Los Altos, CA 94022, USA  
Artera® All Rights Reserved. 5/25.

